Patients & Caregivers
Contact Us
Français
Home
Overview
Major Accomplishments
Working at Merck Frosst
Search Jobs, Submit Resume, Log on
Career Choices
Students and recent Grads
Careers Questions
Partners
Company Overview
Community Relations
Frequently Asked Questions
VIOXX® Information Center
Corporate News
Executive Speeches
Product News
Research & Development News
Media Contact
Newsroom
Corporate News
Photos
Executive Speeches
Product News
CANCIDAS
®
COSOPT
®
COZAAR
®
CRIXIVAN
®
EMEND
®
FOSAMAX
®
FOSAVANCE
®
GARDASIL
®
INVANZ
®
ISENTRESS
®
JANUMET
TM
JANUVIA
®
MAXALT
®
PROPECIA
®
PROSCAR
®
ROTATEQ
®
SIMPONI™
SINGULAIR
®
VARIVAX
®
III
VASOTEC
®
VIOXX
®
ZOCOR
®
ZOLINZA
®
ZOSTAVAX
TM
EZETROL
®
Research & Development News
Media Contact
Research & Development News
August 11, 2010
Merck Reports that Two Pivotal Phase III Registration Studies for Boceprevir Have Been Completed and Meet the Primary Endpoints
Printer friendly
This site is for residents of Canada. / This site was updated on August 25, 2010.
